VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death

Brain Research

Volumn 838, Issue 1-2, 1999, Pages 27-36

  Brenneman, Douglas E ^a   Hauser, Janet ^a   Spong, Catherine Y ^a   Phillips, Terry M ^b   Pert, Candace B ^c   Ruff, Michael ^c  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acquired immunodeficiency syndrome; Chemokine; Gp120; Peptide T; Secretion; Vasoactive intestinal peptide

Indexed keywords

CHEMOKINE RECEPTOR; DEXTRO ALANYL PEPTIDE T AMIDE; GLYCOPROTEIN GP 120; ISOPROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ARTICLE; ASTROCYTE; CELL COUNT; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS 1; NERVE CELL NECROSIS; NEUROPROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT; RECEPTOR BINDING;

ANIMALS; CELL DEATH; CELLS, CULTURED; CHEMOKINES; HIV; HIV ENVELOPE PROTEIN GP120; NEURONS; NEUROTOXINS; PEPTIDE T; RANTES; RATS; VARIATION (GENETICS); VASOACTIVE INTESTINAL PEPTIDE;

EID: 0033554205     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01644-3     Document Type: Article

References (55)

1. Achim C.L., Wang R., Miners D.K., Wiley C.A. Brain viral burden in HIV-infection. J. Neuropathol. Exp. Neurol. 53:1994;284-294.
2. Agnati L.F., Zoli M., Stromberg I., Fuxe K. Intercellular communication in the brain: wiring versus volume transmission. Neuroscience. 69:1995;711-726.
3. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., Berger E.A. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 272:1996;1955-1958.
4. Bagetta G., Corasaniti M.T., Malorni W., Rainaldi G., Berliocchi L., FinazziAgro A., Nistico G. The HIV-1 gp120 causes ultrastructural changes typical of apoptosis in the rat cerebral cortex. Neuroreport. 7:1996;1722-1724.
5. Brenneman D.E., Buzy J.M., Ruff M.R., Pert C.B. Peptide T sequences prevent neuronal cell death produced by the envelope protein (gp120) of the human immunodeficiency virus. Drug Dev. Res. 15:1988;361-369. Abstract.
6. Brenneman D.E., Eiden L.E. Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc. Natl. Acad. Sci. USA. 83:1986;1159-1162.
7. Brenneman D.E., Gozes I. A femtomolar-acting neuroprotective peptide. J. Clin. Invest. 97:1996;2299-2307. see comments.
8. Brenneman D.E., Hill J.M., Glazner G.W., Gozes I., Phillips T.W. Interleukin-1 alpha and vasoactive intestinal peptide: enigmatic regulation of neuronal survival. Int. J. Dev. Neurosci. 13:1995;187-200.
9. Brenneman D.E., McCune S.K., Mervis R.F., Hill J.M. gp120 as an etiologic agent for NeuroAIDS: neurotoxicity and model systems. Adv. Neuroimmunol. 4:1994;157-165.
10. Brenneman D.E., Nicol T., Warren D., Bowers L.M. Vasoactive intestinal peptide: a neurotrophic releasing agent and an astroglial mitogen. J. Neurosci. Res. 25:1990;386-394.
11. Brenneman D.E., Westbrook G.L., Fitzgerald S.P., Ennist D.L., Elkins K.L., Ruff M.R., Pert C.B. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature. 335:1988;639-642.
12. Broder C.C., Collman R.G. Chemokine receptors and HIV. J. Leukoc. Biol. 62:1997;20-29.
13. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P.D., Wu L., Mackay C.R., LaRosa G., Newman W., Gerard N., Gerard C., Sodroski J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 85:1996;1135-1148.
14. Cocchi F., DeVico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 270:1995;1811-1815. see comments.
15. Deng H.K., Unutmaz D., KewalRamani V.N., Littman D.R. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature. 388:1997;296-300. see comments.
16. Dittmar M.T., McKnight A., Simmons G., Clapham P.R., Weiss R.A., Simmonds P. HIV-1 tropism and co-receptor use. Nature. 385:1997;495-496. letter.
17. Doranz B.J., Lu Z.H., Rucker J., Zhang T.Y., Sharron M., Cen Y.H., Wang Z.X., Guo H.H., Du J.G., Accavitti M.A., Doms R.W., Peiper S.C. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J. Virol. 71:1997;6305-6314.
18. Dreyer E.B., Kaiser P.K., Offermann J.T., Lipton S.A. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science. 248:1990;364-367. see comments.
19. Festoff B.W., Nelson P.G., Brenneman D.E. Prevention of activity-dependent neuronal death: vasoactive intestinal polypeptide stimulates astrocytes to secrete the thrombin-inhibiting neurotrophic serpin, protease nexin I. J. Neurobiol. 30:1996;255-266.
20. Galasso J.M., Harrison J.K., Silverstein F.S. Excitotoxic brain injury stimulates expression of the chemokine receptor CCR5 in neonatal rats. Am. J. Pathol. 153:1998;1631-1640.
21. Giulian D., Vaca K., Noonan C.A. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science. 250:1990;1593-1596.
22. Gozes I., Bardea A., Bechar M., Pearl O., Reshef A., Zamostiano R., Davidson A., Rubinraut S., Giladi E., Fridkin M., Brenneman D.E. Neuropeptides and neuronal survival: neuroprotective strategy for Alzheimer's disease. Ann. N.Y. Acad. Sci. 814:1997;161-166.
23. Gozes I., Lilling G., Glazer R., Ticher A., Ashkenazi I.E., Davidson A., Rubinraut S., Fridkin M., Brenneman D.E. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J. Pharmacol. Exp. Ther. 273:1995;161-167.
24. Gozes I., McCune S.K., Jacobson L., Warren D., Moody T.W., Fridkin M., Brenneman D.E. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J. Pharmacol. Exp. Ther. 257:1991;959-966.
25. Grimaldi M., Florio T., Schettini G. Somatostatin inhibits interleukin 6 release from rat cortical type I astrocytes via the inhibition of adenylyl cyclase. Biochem. Biophys. Res. Commun. 235:1997;242-248.
26. Grimaldi M., Pozzoli G., Navarra P., Preziosi P., Schettini G. Vasoactive intestinal peptide and forskolin stimulate interleukin 6 production by rat cortical astrocytes in culture via a cyclic AMP-dependent, prostaglandin-independent mechanism. J. Neurochem. 63:1994;344-350.
27. He J., Chen Y., Farzan M., Choe H., Ohagen A., Gartner S., Busciglio J., Yang X., Hofmann W., Newman W., Mackay C.R., Sodroski J., Gabuzda D. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature. 385:1997;645-649.
28. Heseltine P.N.R., Goodkin K., Atkinson J.H., Vitiello B., Rochon J., Heaton R.K., Eaton E.M., Wilkie F.L., Sobel E., Brown S.J., Feaster D., Schneider L., Goldschmidts W.L., Stover E.S. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch. Neurol. 55:1998;41-51.
29. Hesselgesser J., Taub D., Baskar P., Greenberg M., Hoxie J., Kolson D.L., Horuk R. Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr. Biol. 8:1998;595-598.
30. Hill J.M., Mervis R.F., Avidor R., Moody T.W., Brenneman D.E. HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. Brain Res. 603:1993;222-233.
31. Horuk R., Martin A.W., Wang Z., Schweitzer L., Gerassimides A., Guo H., Lu Z., Hesselgesser J., Perez H.D., Kim J., Parker J., Hadley T.J., Peiper S.C. Expression of chemokine receptors by subsets of neurons in the central nervous system. J. Immunol. 158:1997;2882-2890.
32. Jiang Y., Salafranca M.N., Adhikari S., Xia Y.Y., Feng L.L., Sonntag M.K., deFiebre C.M., Pennell N.A., Streit W.J., Harrison J.K. Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis. J. Neuroimmunol. 86:1998;1-12.
33. Kosten T.R., Rosen M.I., McMahon T.L., Bridge T.P., O'Malley S.S., Pearsall R., O'Connor P.G. Treatment of early AIDS dementia in intravenous drug users: high versus low dose peptide T. Am. J. Drug Alcohol Abuse. 23:1997;543-553.
34. Lampley E.C. Jr., Mishra O.P., Graham E., Delivoria-Papadopoulos M. Neuroprotective effect of phenytoin against in utero hypoxic brain injury in fetal guinea pigs. Neurosci. Lett. 186:1995;192-196.
35. Lannuzel A., Barnier J.V., Hery C., Van Tan H., Guibert B., Gray F., Vincent J.D., Tardieu M. Human immunodeficiency virus type 1 and its coat protein gp120 induce apoptosis and activate JNK and ERK mitogen-activated protein kinases in human neurons. Ann. Neurol. 42:1997;847-856.
36. Lipton S.A. Requirement for macrophages in neuronal injury induced by HIV envelope protein gp120. Neuroreport. 3:1992;913-915.
37. Lipton S.A., Sucher N.J., Kaiser P.K., Dreyer E.B. Synergistic effects of HIV coat protein and NMDA receptor-mediated neurotoxicity. Neuron. 7:1991;111-118.
38. Luber-Narod J., Kage R., Leeman S.E. Substance P enhances the secretion of tumor necrosis factor-alpha from neuroglial cells stimulated with lipopolysaccharide. J. Immunol. 152:1994;819-824.
39. Meucci O., Fatatis A., Simen A.A., Bushell T.J., Gray P.W., Miller R.J. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc. Natl. Acad. Sci. USA. 95:1998;14500-14505.
40. Mulroney S.E., McDonnell K.J., Pert C.B., Ruff M.R., Resch Z., Samson W.K., Lumpkin M.D. HIV gp120 inhibits the somatotropic axis: a possible GH-releasing hormone receptor mechanism for the pathogenesis of AIDS wasting. Proc. Natl. Acad. Sci. USA. 95:1998;1927-1932.
41. Pert C.B., Hill J.M., Ruff M.R., Berman R.M., Robey W.G., Arthur L.O., Ruscetti F.W., Farrar W.L. Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity. Proc. Natl. Acad. Sci. USA. 83:1986;9254-9258.
42. Phillips T.M., Kimmel P.L. High-performance capillary electrophoretic analysis of inflammatory cytokines in human biopsies. J. Chromatogr. B. Biomed. Appl. 656:1994;259-266.
43. Reeves J.D., McKnight A., Potempa S., Simmons G., Gray P.W., Power C.A., Wells T., Weiss R.A., Talbot S.J. CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. Virology. 231:1997;130-134.
44. Romijn H.J., van Huizen F., Wolters P.S. Towards an improved serum-free, chemically defined medium for long-term culturing of cerebral cortex tissue. Neurosci. Biobehav. Rev. 8:1984;301-334.
45. Ruff M.R., Hallberg P.L., Hill J.M., Pert C.B. Peptide T4-8 is core HIV envelope sequence required for CD4 receptor attachment. Lancet. 2:1987;751. letter.
46. Ruff M.R., Martin B.M., Ginns E.I., Farrar W.L., Pert C.B. CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxis. Relationship to vasoactive intestinal polypeptide. FEBS Lett. 211:1987;17-22.
47. Schmechel D., Marangos P.J., Zis A.P., Brightman M., Goodwin F.K. Brain endolases as specific markers of neuronal and glial cells. Science. 199:1978;313-315.
48. Smith C.C., Hallberg P.L., Sternberg E.M., Martin B.M., Pert C.B., Ruff M.R. Tritiated D-(ala1)-peptide T binding: a pharmacologic basis for the design of drugs which inhibit HIV receptor binding. Drug Dev. Res. 15:1988;371-379.
49. Tallant E.A., Higson J.T. Angiotensin II activates distinct signal transduction pathways in astrocytes isolated from neonatal rat brain. Glia. 19:1997;333-342.
50. Trkola A., Dragic T., Arthos J., Binley J.M., Olson W.C., Allaway G.P., Cheng-Mayer C., Robinson J., Maddon P.J., Moore J.P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 384:1996;184-187. see comments.
51. Villemagne V.L., Phillips R.L., Liu X., Gilson S.F., Dannals R.F., Wong D.F., Harris P.J., Ruff M., Pert C., Bridge P., London E.D. Peptide T and glucose metabolism in AIDS dementia complex. J. Nucl. Med. 37:1996;1177-1180.
52. Vincent J.D., Lannuzel A., Barnier J.V., Lledo P.M., Tardieu M. Toxicity of HIV1 envelope protein gp120 for human neurones in vitro. Bull. Acad. Natl. Med. 181:1997;713-724.
53. Weglicki W.B., Phillips T.M. Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am. J. Physiol. 263:1992;R734-R737.
54. Wiley C.A., Schrier R.D., Nelson J.A., Lampert P.W., Oldstone M.B. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc. Natl. Acad. Sci. USA. 83:1986;7089-7093.
55. Yeung M.C., Pulliam L., Lau A.S. The HIV envelope protein gp120 is toxic to human brain-cell cultures through the induction of interleukin-6 and tumor necrosis factor-alpha. AIDS. 9:1995;137-143.